Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 0.72%.

  • Axsome Therapeutics' Return on Capital Employed rose 1300.0% to 0.72% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72%, marking a year-over-year increase of 1300.0%. This contributed to the annual value of 0.81% for FY2024, which is 800.0% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Return on Capital Employed of 0.72% as of Q3 2025, which was up 1300.0% from 0.83% recorded in Q2 2025.
  • Axsome Therapeutics' Return on Capital Employed's 5-year high stood at 0.39% during Q3 2023, with a 5-year trough of 0.85% in Q3 2024.
  • Its 4-year average for Return on Capital Employed is 0.69%, with a median of 0.74% in 2022.
  • In the last 5 years, Axsome Therapeutics' Return on Capital Employed surged by 2400bps in 2023 and then plummeted by -4600bps in 2024.
  • Axsome Therapeutics' Return on Capital Employed (Quarter) stood at 0.75% in 2022, then soared by 32bps to 0.51% in 2023, then plummeted by -65bps to 0.84% in 2024, then rose by 14bps to 0.72% in 2025.
  • Its Return on Capital Employed was 0.72% in Q3 2025, compared to 0.83% in Q2 2025 and 0.8% in Q1 2025.